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Needle and syringe programs (NSPs) are among the most effective interventions to control infection 
transmission among people who inject drugs in prisons. This review aimed to evaluate the availability, 
accessibility, and coverage of NSP in prisons in the European Union countries. In line with the 
“Preferred Reporting Items for Systematic Reviews and Meta-Analyses” criteria, four databases of 
peer-reviewed publications (PubMed/Medline, ISI Web of Science, EBSCO, and ScienceDirect), and 
53 databases for grey literature were systematically searched to collect data published from January 
2008 to August 2018. A total of 23,969 documents (17,297 papers and 6,672 grey documents) were 
identified, of them 26 were included into the study. In 2018, imprisonment rates in 28 EU countries 
ranged between 51 per 100,000 in Finland and 235 per 100,000 in Lithuania. Only four countries 
namely Germany (in one prison), Luxemburg (no coverage data were found), Romania (available in 
more than 50% of prisons), and Spain (in all prisons) have needle and syringe programs in prisons. 
Portugal stopped the program after a six-months pilot phase. Despite the protective impact of the prison-
based NSP on infection transmission, only four EU countries distribute sterile syringes among people 
who inject drugs in prisons, and coverage of the program within these countries is very low. Since most 
prisoners will eventually return to the community, lack of NSP in EU prisons is not only a threat to the 
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On any given day, around 11 million people throughout the world are held in prisons and other closed 
settings.1 In comparison with the general population, people behind bars are more likely to engage in 
high-risk behaviors such as unprotected sex, sharing needles/syringes for injecting drug use, and unsafe 
tattooing, piercing,2-4 as well as the other forms of skin penetration.5,6 A recent estimate was that the 
prevalence of injection drug use among prisoners varies across UN Regions between 0.5% and 20.2%; 
sexual risk behaviors between 1.5% and 13.6%; and tattooing between 14.7% and 45.4%.3 These risk 
behaviors put prisoners at an elevated risk for acquiring the major infectious diseases including 
HIV/AIDS and viral hepatitis. A global study estimated that 3.8% of the global prison population 
(389,000 prisoners) are living with HIV, 15·1% (1,546,500) with hepatitis C virus (HCV), 4·8% 
(491,500) with chronic hepatitis B virus (HBV), and 2·8% (286,000) with active tuberculosis.7 The 
aforementioned study suggested that high prevalence of the major infectious diseases in prisons is 
related to the criminalization of drug use and imprisonment of people who use drugs. Accordingly, a 
decrease in the incarceration rate of people who use or inject drugs, as well as applying a comprehensive 
package of interventions including in-prison drug treatment and needle and syringe programs (NSP) 
can considerably reduce infection transmission in prisons around the world.7 
 
Prevalence of the major infectious diseases and risk behaviors, specifically drug injection, in prisons in 
Europe is a serious cause for concern. Evidence shows that 9.3% of prisoners in Western and Central 
Europe and North American region inject drugs in prison.3 The prevalence of HIV and HCV in Western 
Europe has been estimated at 4.2% and 15.5% among people who inject drugs (PWIDS), respectively, 
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which are higher than the global prison average (HIV: 3.8% and HCV: 15.1%).7 This evidence 
highlights the importance of attention to European prisons as a potential source of infection 
transmission, and a threat to public health. 
 
Needle and syringe programs are among the most effective interventions in preventing infection 
transmission both inside and outside prison.2 Findings from a global systematic review and meta 
analysis showed an association between higher coverage of NSP and a reduction in HCV acquisition 
among people who inject drugs in the community.8 The evaluation of prison-based NSPs in three 
European countries showed a set of positive outcomes including: a decline in needle sharing, no new 
cases of HIV or viral hepatitis transmission, and no reports of serious unintended negative events such 
as using needles as weapons to threaten prison staff or other prisoners.9 Although the NSP, as an 
effective intervention against infection transmission, has been recommended by international 
organizations including WHO, Joint United Nations Programme on HIV/AIDS (UNAIDS), and the 
United Nations Office on Drugs and Crime (UNODC), it has been implemented in prisons in just a few 
countries in the world.2 
 
In 2013, the UNODC developed a comprehensive package of interventions to control HIV/AIDS, 
Hepatitis B, Hepatitis C, and Tuberculosis in prisons.10 The Package contained 15 interventions 
including NSP as a necessary intervention to mitigate the burden of infectious diseases in prisons. This 
study reviews and reports the availability, accessibility, and coverage of NSP in prisons in 28 EU 
countries, and identifies the key obstacles to implementation of NSP in these countries. 
 
 
Materials and Methods 
 
The present study is drawn from the comprehensive systematic scoping review of availability, 
accessibility and coverage of key interventions to control HIV and relevant infections within the EU 
prisons. It was conducted in line with the “Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA)” criteria.11 
 
Geographical coverage of the study 
 
Our review covers 28 European countries (namely Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, 
Sweden, and the United Kingdom) listed as the member states of the European Union at the end of 
2018.12 In this review, publications and reports from all penal institutions including prisons, jails, police 
cells, and detention centers were assessed. 
 
Systematic Literature Search 
 
Peer-reviewed and grey literature were searched to find data on availability and coverage of NSP in 
prisons in the EU countries. The UNODC global dataset on epidemiology and risk factors of the major 
infectious diseases in prison was used as a complementary dataset. 
 
The initial search took place in August 2018. Four databases including the Institute of Scientific 
Information (ISI) Web of Science, Medline via PubMed, EBSCO and ScienceDirect as the main 
databases of peer-reviewed publications were searched to identify papers published between January 
2008 and August 2018. Over 300 search terms were used in the aforementioned databases. A complete 
list of search terms is available in Web Appendix 1. To search the grey literature, we followed the 
guidelines “Searching the grey literature to access information on drugs, alcohol and HIV/AIDS 
research: An update”, developed by the National Drug and Alcohol Research Center; University of New 
South Wales.13 In addition to Google and Google Scholar, 53 global, European, and country-specific 
databases recommended by the guidelines were searched to identify unpublished data. The grey 
literature search took place between April and June 2019. 
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As the complementary source of data used in this study, the UNODC global dataset contains 
information about epidemiology and risk factors of HIV, TB and viral hepatitis in prisons. Data 
summarized in the UNODC global dataset were gathered through a global systematic review of the 
literature published from 2013 to 2017, as well as surveying key informants in each region and/or 




In order to minimize the risk of missing important data, first we conducted the review at a global level, 
then we excluded the documents from the countries outside the EU. We used a set of broad inclusion 
criteria to ensure an exhaustive review of NSP in the EU prisons. All documents containing information 
about availability, accessibility and coverage of NSP in any EU country were included. The documents 
reporting data from outside the EU, data collection before 2008, and those without relevant information, 
listed authors, or valid references were excluded. Peer-reviewed references were managed by EndNote 
(Clarivate Analytics, Philadelphia, PA) version X8.2 for Windows. 
 
In case of unavailability of the full texts or any question regarding the methodology or results of the 
obtained documents, corresponding authors were contacted through email or ResearchGate message to 
provide the full text or more information regarding their projects. Besides, controversial results were 
cross-checked by the European harm-reduction experts, and updated based on their knowledge and 
experience. 
 
Definition of the outcomes 
 
‘Availability’ refers to whether or not sterile syringes were distributed among PWIDs in prisons through 
an official program aimed to decrease the burden of infectious diseases in prison. ‘Accessibility’ means 
the method of syringe distribution (e.g. through healthcare workers on demand, or syringe vending 
machines) by which PWIDs can have access to sterile syringes. ‘Coverage’ refers to the proportion of 
prisons (number of prisons providing NSP divided by number of all prisons in a certain country) or the 
proportion of PWIDs (number of PWIDs who are under coverage of NSP divided by number of all 





A total of 23,969 documents including 17,297 peer-reviewed and 6,672 grey literature publications 
were identified through the systematic search. From all publications 22,710 were excluded after 
reviewing the titles, 755 by abstract, and 478 by full text. Finally, 26 publications on NSP in the EU 
prisons were included in qualitative synthesis (Figure 1). Our search included publications in German, 
French, Spanish, Portuguese, Finnish, Lithuanian, Polish, and Greek as well as English. 
 
Imprisonment rates in the EU 
 
Understanding the rates of imprisonment in the EU countries allows for assessment of harm reduction 
interventions in prisons. According to the latest World Prison Population report from the International 
Centre for Prison Studies in 2018, imprisonment rates in the EU countries ranged from 51 per 100,000 
population in Finland to 235 per 100,000 population in Lithuania.1 Poland with 73,524 and Malta with 
588 prisoners had the highest and lowest number of prisoners within the EU countries.1 
 
NSP in the EU prison 
 
Only four countries including Germany, Luxemburg, Romania, and Spain have needle and syringe 
programs in prisons. One country (Portugal) stopped the program after a pilot phase (Table 1). Of all 
26 included publications on NSP in the EU prisons, 9 national and 2 sub-national reports were from 
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Spain, 6 national reports from Germany, 5 national reports from Romania, 2 national reports from 




Prevalence of prisoners who have ever injected drugs in Germany was 22.2%.14 Germany has NSP in 
prisons.15-17 The program was started in 1996 with a pilot phase in two (one men’s and one women’s) 
prisons. The pilot program was found to be successful by an independent evaluation, as needle sharing 
and overdose decreased drastically, and no attack with needles by clients of the program was recorded.9 
Syringes were distributed through drug and alcohol counsellors in the men’s prison, and an automatic 
dispenser in the women’s prison.9 
 
Data on coverage of the program in this country is controversial. A survey of 25 countries in 2018 
reported that the program is currently implemented in at least one prison in Germany.18 Another report, 
however, stated that only women in ‘some’ German prisons have access to sterile needle and syringes.19 
The absolute numbers regarding the coverage of NSP in German prisons were obtained from an article 
published by Stark and colleagues, who estimated that in the first 4 months after starting the pilot phase 
in two German prisons, coverage of the program dropped from 71% (of PWIDs in prisons) to 11%.20 
Consulting with the European experts revealed that only one prison (Berlin-Lichtenberg women’s 
prison) in Germany has NSP. No information was found regarding the possible reasons for the reduction 




In Luxemburg, the prevalence of prisoners who had ever injected drugs was estimated at 31%.14 
Availability of NSP in prisons in Luxemburg has been documented by a report from the WHO in 2008 
and an article published by Michels and Stöver published in 2012.16, 17 However, none of these 
documents reported data on coverage of the prison NSP in this country. No information was found 
regarding the initiation date of the program, number of PWIDs in prisons under NSP, or funding source 




We found no data regarding the rate of injection drug use in prisons in Romania; however, this country 
is another EU country with NSP in prison.16, 21 Similar to the previous countries, data on the coverage 
of the program in prisons of Romania is controversial. A cross-sectional survey of harm reduction in 
25 countries authored by Bielen and colleagues in 2018 reported that NSP is officially available in all 
prisons in Romania, but has no clients since prisoners need to fill in enrolment forms and disclose their 
personal information and are reluctant to do so.18 Another study, however, reported that NSP is available 
in 8 out of 44 national penal institutions (18%) in Romania.15 On the other hand, the WHO Regional 
Office for Europe claimed that NSP is implemented in more than half of prisons in Romania.22 
Consulting with the European experts confirmed findings of Bielen and colleagues that needle and 
syringe program in Romania has no client. We found no other information regarding the details of the 




In Spain, prevalence of ever injection drug use in prison was found to be 3.1%.14 Availability of NSP 
in Spanish prisons has been documented by 11 publications. 15, 17-19, 22-27 According to the findings, Spain 
is the only EU country providing NSP in all prisons.18, 22 Assessment of the need and coverage of syringe 
exchange program in Spanish prisons conducted by de la Fuente and colleagues in 2012 showed that 
NSP was started in 1997, its maximum coverage reached 36% in 2005, and it was halved during the 
next four years, to 17.4% in 2009.24 Another article reported that maximum coverage of NSP reached 
20.7% in 2006, but halved in the next two years.25 Although NSP exists in all prisons in Spain, a small 
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proportion of Spanish PWIDs in prisons use this service. No evidence was found regarding the reasons 




Prevalence of injection drug use in prisons in Portugal was estimated at 1.9%.14 In December 2007 a 
pilot prison NSP was mandated by the Parliament of Portugal; however, six months after starting the 
pilot phase the prison healthcare system decided to terminate the program.15, 27 Despite guarantee of the 
confidentiality of personal data, no prisoners participated in the pilot study, which led to termination of 
the program.27 Lack of participation of PWIDs in prisons in the pilot NSP was in fact because of the 





Our review reveals that no EU country has a fully implemented and/or systematic NSP program in 
prison. Evidence from our review indicate that at least five of 28 members of the European Union 
including Germany, Luxemburg, Portugal, Romania and Spain have implemented needle and syringe 
program in prisons, while Portugal’s program did not start due to the lack of willing participants. In 
most EU countries with NSP in prisons, coverage of the program dropped over time. Coverage of NSP 
is found to be low in prisons in Germany, Romania, and Spain, and unknown in Luxemburg. 
 
Detailed information is required to perform an accurate multi-dimensional assessment of needle and 
syringe programs in prisons. Such information should include number of PWIDs in each facility, and 
the proportion covered by NSP; number of syringes distributed in a defined period of time; which 
organization is in charge; what is financial cost of the program; the method of syringe distribution (e.g. 
through vending machines, healthcare providers on demand); whether the sterile syringes are free of 
charge; disposal methods and information about satisfaction of custodial staff and clients of the 
program; as well as effectiveness of the program to control infection transmission in prisons. 
Information regarding the above-mentioned topics in four EU countries implementing NSP in prisons 
is scarce and now dated. Obviously more research is required to bridge the gaps in data and to enhance 
the effectiveness of NSP in prisons in the EU countries. 
 
The availability of prison-based NSP in only four European Union countries, and low coverage of the 
programs in these countries is a serious cause for public health concern. Prison authorities may have 
three main concerns about implementation of NSP in prisons: 1. Syringes will be used as weapons 
against prison guards or other prisoners; 2. Provision of syringes may increase the number of people 
injecting drugs in prisons; 3. Implementation of NSP would admit security failure and presence of drugs 
in prison. In response to these concerns, it should be noted that there are no reports from EU countries 
with prison-based NSP where syringes were used as weapons, or that provision of syringes increased 
the frequency of drug use in prisons.28 Furthermore, availability and use of the other harm-reduction 
services such as opioid substitution treatment, bleach for syringe cleaning or drug-free units already 
confirm that drugs are available in prisons.28 
 
The resistance to prison-based NSP also relates to the wider political difficulties of mainstreaming harm 
reduction approaches in prison settings. In the UK for example, the dominant policy focus has been on 
promoting abstinence and eradicating drugs in prisons by increasing security, testing and punishment, 
rather than harm reduction measures which were viewed as politically untenable as implementing them 
would appear to be encouraging and condoning illegal drug use. 29,30 In relation to NSP, the Prison 
Service concluded that ‘the conflict between encouraging prisoners to use an exchange scheme and 
detecting illicit drug use would have no easy resolution’.31 As mentioned above, there was also 
opposition from prison officers due to fears of needles being used as weapons. As a compromise, after 
an outbreak of HIV infection in Scotland in 1993 due to in-prison injecting, sterilizing tablets were 
eventually made available to clean injecting equipment.32 
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Sterile syringes can be distributed among prisoners through various methods including syringe 
dispensing machines, peer workers, non-governmental organizations and external personnel, and prison 
healthcare providers. As discussed previously, because of the lack of confidentiality no prisoner 
participated in NSP in Portugal, and consequently the prison health policymakers terminated the 
program, due to the lack of participants.27 Similarly, there was reluctance of male PWIDs in prisons in 
Germany to engage in the program due to the lack of anonymity.9 Considering the experiences of 
Portugal and Germany, distribution of syringes via requests to healthcare staff members is not advisable 
for implementing NSP in prisons. Using syringe dispensing machines in a private place (e.g. prison 
toilets) can increase the participation and enhance the effectiveness of the program. 
 
According to the WHO, an effective health intervention has four main components; availability, 
accessibility, acceptability, and quality.33 In terms of availability, sterile syringes should be available to 
all PWIDs in prisons (regardless of their age, gender, type of crime, sentence length, etc.) at any given 
time. Lack of HIV knowledge and lack of confidentiality could be among the barriers to accessibility 
to sterile injection equipment and acceptability of NSP programs. Implementation of NSP in prisons is 
not only away to control infections, but also is a prisoners’ right to access high-quality healthcare, 
equivalent to that available in the community. According to the UN’s International Bill of Human 
Rights, all prisoners have right to the highest standards of physical and mental healthcare.34 United 
Nations Standard Minimum Rules for the Treatment of Prisoners (the Nelson Mandela Rules) rule 24 
states that: “Prisoners should enjoy the same standards of health care that are available in the 
community, and should have access to necessary health-care services free of charge without 
discrimination on the grounds of their legal status”.35  
 
Since implementation of needle and syringe programs to control bloodborne infections in prisons is a 
part of the highest standards of healthcare, it is argued that all governments are obliged to provide them 
to prisoners.28 Effectiveness of needle and syringe programs to decrease the burden of infectious 
diseases is well established. However, evidence shows that a combination of health intervention is more 
effective than a single intervention.36-38 For example, results of a network population simulation 
experiment in the United States suggest that combined syringe access and medically assisted treatment are 
much more effective than each single intervention to reduce HCV transmission among injecting drug users.39 
Findings of another study evaluating the effectiveness of opiate substitution therapy, high-coverage 
needle and syringe programs, and antiviral treatment of HCV confirmed that combined interventions 
are more effective to reduce the burden of HCV among those who inject drugs.40 According to the 
abovementioned evidence, NSP should be combined with the other effective interventions such as 
information, education and risk communication, and opioid substitution treatment. 
 
In the past 20 years, the effectiveness of prison-based NSP has been evaluated in various countries in 
which it has been implemented. The experience of eight countries with needle and syringe programs in 
prisons showed that these programs: 1) have additional positive health impacts on prisoners through 
referring them to drug treatment and the other healthcare services; 2) are effective in different prison 
systems; and 3) can be modified based on the needs of institutions and prisoners.41 Drawing the attention 
of prison health policy makers to the positive health impacts of NSP might encourage them to 
implement programs or increase the accessibility and quality of the programs in the EU countries with 
low coverage and quality. 
 
The UN comprehensive package of interventions is one of the most quoted references about infection 
control in prisons and closed settings. In addition to NSP, the other services such as Information, 
education and risk communication; prevention, diagnosis and treatment of HIV/AIDS, viral hepatitis 
and tuberculosis; drug dependence treatment, including opioid substitution therapy; are among the 
interventions in the comprehensive package.10 Although the guidelines cover a broad list of issues, some 
major elements such as alcohol use, psychiatric disorders, sexual partners of prisoners, and after-release 
period are missing in the package of interventions.42 Considering NSP as one of the main interventions 
to control infection transmission in prisons, policy makers are recommended to consider the 
shortcomings of the existing guidelines in order to maximize efficacy of combined interventions to 




Of all 28 European Union countries, only four have implemented NSP is prisons, which is a cause for 
public health concern in this region. Lack of availability and coverage of NSP in the EU prisons can be 
the result of misconceptions of policy makers about prisoners using syringes as weapons or the 
programs encouraging prisoners to start using drugs. Providing sterile syringes in prisons is not only an 
intervention to control infection transmission, but also a prisoner’s right to access high-quality 
healthcare. It is recommended that prison authorities in the EU countries implement or expand the 
coverage of NSP as an evidence-based intervention to control infectious diseases in prisons. Prisoners 
should be involved in the design and implementation of prison-based NSP, as well as having easy and 
confidential access to syringes. Since most prisoners will eventually return to the community, 
implementation of accessible, acceptable and high-quality NSP with maximum coverage in prisons in 
the EU countries should be considered as a public health intervention. 
 
Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of 
studies published 2008-2018 and included in this review 
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Table 1. Characteristics of the countries with past or current NSP in prisons 
Country Imprisonment Rate 
(per 100,000)1 




NSP coverage in 
prisons 
comments 
Germany 75 22.2 Yes15-17 At least 1 prison 
Luxemburg 107 31 Yes16,17 Not available 
Portugal 127 1.9 No15,27 Program stopped in 2007 after a pilot phase. 
Romania 111 NA Yes16,21 0%->50% of 
prisons 
Spain 126 3.1 Yes15,17-19,22-27 17.4%-36% of 
prisoners 
Records Identified Through 
Database Searching 
PubMed/MEDLINE (n = 5,114) 
ISI Web of Science (n = 5,798) 
EBSCO (n = 5,750) 
ScienceDirect (n = 4,546) 
Included Eligibility Screening Identification 
Records Identified Through 
Gray Literature Searching 
(n = 6,672) 
Records After Duplicates 
Removed (n = 23,969) 
Records Excluded Because of 
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Irrelevant Titles (n = 22,765) 
Abstract Screened 
(n = 1,204) 
Records Excluded 
Data from outside the EU (n = 148) 
Collected before 2008 (n = 49) 
Lack of valid references (n = 71) 
No authors listed (n = 6) 
Full-Text Articles Irrelevant content (n = 481) 
Assessed for Eligibility 
(n = 449) 
Studies Included in 
Qualitative Synthesis 
(n = 26) 
Records Excluded Because of 
Irrelevant Content or Outdated 
Data (n = 423) 


























HIV OR Human Immunodeficiency Virus OR Immunodeficiency Virus, Human OR Immunodeficiency 
Viruses, Human OR Virus, Human Immunodeficiency OR Viruses, Human Immunodeficiency OR Human 
Immunodeficiency Viruses OR AIDS Virus OR AIDS Viruses OR Virus, AIDS OR Viruses, AIDS OR 
Acquired Immune Deficiency Syndrome Virus OR Acquired Immunodeficiency Syndrome Virus OR 
Acquired Immunodeficiency Syndrome OR Immunologic Deficiency Syndrome, Acquired OR Acquired 
Immune Deficiency Syndrome OR Acquired Immuno-Deficiency Syndrome OR Acquired Immuno 
Deficiency Syndrome OR Acquired Immuno-Deficiency Syndromes OR Immuno-Deficiency Syndrome, 
Acquired OR Immuno-Deficiency Syndromes, Acquired OR Syndrome, Acquired Immuno-Deficiency OR 
Syndromes, Acquired Immuno-Deficiency OR Immunodeficiency Syndrome, Acquired OR Acquired 
Immunodeficiency Syndromes OR Immunodeficiency Syndromes, Acquired OR Syndrome, Acquired 
Immunodeficiency OR Syndromes, Acquired Immunodeficiency 
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TB 
Tuberculosis OR Tuberculoses OR Kochs Disease OR Disease, Kochs OR Koch's Disease OR Disease, 
Koch's OR Koch Disease OR Latent Tuberculosis OR Latent Tuberculoses OR Tuberculoses, Latent OR 
Tuberculosis, Latent OR Latent Tuberculosis Infection OR Infection, Latent Tuberculosis OR Infections, 
Latent Tuberculosis OR Latent Tuberculosis Infections OR Tuberculosis Infection, Latent OR 
Tuberculosis Infections, Latent 
Hepatitis 
Hepatitis OR Hepatitides OR Chronic Hepatitis OR Cryptogenic Chronic Hepatitis OR Chronic Hepatitis, 
Cryptogenic OR Hepatitis, Cryptogenic Chronic OR Hepatitis, Chronic, Cryptogenic OR Hepatitis, Chronic 
Active OR Chronic Active Hepatitis OR Hepatitis, Chronic Persistent OR Chronic Persistent Hepatitides 
OR Chronic Persistent Hepatitis OR Hepatitis B, Chronic OR Chronic Hepatitis B OR Hepatitis B OR 
Hepatitis C, Chronic OR Chronic Hepatitis C OR Parenterally-Transmitted Non-A, Non-B Hepatitis OR 
Parenterally Transmitted Non A, Non B Hepatitis OR PT-NANBH OR Hepatitis, Viral, Non-A, Non-B, 
Parenterally-Transmitted 
Comorbidity/Coinfection 
Comorbidity OR Comorbidities OR Multimorbidity OR Multimorbidities OR Coinfection OR Coinfections 
OR Polymicrobial Infection OR Infection, Polymicrobial OR Infections, Polymicrobial OR Polymicrobial 
Infections OR Co-infection OR Co infection OR Co-infections OR Mixed Infection OR Infection, Mixed OR 
Infections, Mixed OR Mixed Infections OR Secondary Infections OR Infection, Secondary OR Infections, 
Secondary OR Secondary Infection 
Prison 
Prisons OR Prison OR Prison* OR Concentration Camps OR Incarcerate* OR Penitentiary OR 
Penitentiaries OR Jail* OR inmate* OR Inmates OR Correctional setting OR Correctional settings OR 
Correctional Centre OR Correctional Centers OR Incarceration 
IEC 
Information Services OR Information Service OR Service, Information OR Services, Information OR 
Information Specialists OR Information Specialist OR Specialist, Information OR Specialists, Information 
OR Information Networks OR Information Network OR Network, Information OR Networks, Information 
OR Education OR Workshops OR Workshop OR Parenting Education OR Education, Parenting OR 
Training Programs OR Program, Training OR Programs, Training OR Training Program OR Educational 
Activities OR Activities, Educational OR Activity, Educational OR Educational Activity OR Literacy 
Programs OR Literacy Program OR Program, Literacy OR Programs, Literacy OR Communication OR 
Personal Communication OR Communication, Personal OR Communication Programs OR 
Communication Program OR Program, Communication OR Programs, Communication OR 
Communications Personnel OR Personnel, Communications 
Condom 
Condoms OR Condom OR Condom Manufacture OR Manufacture, Condom OR Contraceptive Devices, 
Male OR Contraceptive Device, Male OR Device, Male Contraceptive OR Devices, Male Contraceptive 
OR Male Contraceptive Device OR Male Contraceptive Devices 
Sexual violence 
Rape OR Sex Offenses OR Offense, Sex OR Offenses, Sex OR Sex Offense OR Sexual Violence OR 
Sexual Violences OR Violence, Sexual OR Violences, Sexual OR Sexual Abuse OR Abuse, Sexual OR 
Abuses, Sexual OR Sexual Abuse 
OST 
Opiate Substitution Treatment OR Opiate Substitution Treatments OR Substitution Treatment, Opiate OR 
Substitution Treatments, Opiate OR Treatment, Opiate Substitution OR Treatments, Opiate Substitution 
OR Opioid Substitution Treatment OR Opioid Substitution Treatments OR Substitution Treatment, Opioid 
OR Substitution Treatments, Opioid OR Treatment, Opioid Substitution OR Treatments, Opioid 
Substitution OR Opioid Substitution Therapy OR Opioid Substitution Therapies OR Substitution 
Therapies, Opioid OR Substitution Therapy, Opioid OR Therapies, Opioid Substitution OR Therapy, 
Opioid Substitution OR Opiate Replacement Therapy OR Opiate Replacement Therapies OR 
Replacement Therapies, Opiate OR Replacement Therapy, Opiate OR Therapies, Opiate Replacement 
OR Therapy, Opiate Replacement OR Opioid Replacement Therapy OR Opioid Replacement Therapies 
OR Replacement Therapies, Opioid OR Replacement Therapy, Opioid OR Therapies, Opioid 
Replacement OR Therapy, Opioid Replacement 
NEP 
Needle-Exchange Programs OR Needle Exchange Programs OR Needle-Exchange Program OR 
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Program, Needle-Exchange OR Programs, Needle-Exchange OR Syringe-Exchange Programs OR 
Program, Syringe-Exchange OR Programs, Syringe-Exchange OR Syringe Exchange Programs OR 
Syringe-Exchange Program OR Supervised Injecting Centers OR Center, Supervised Injecting OR 
Centers, Supervised Injecting OR Injecting Center, Supervised OR Injecting Centers, Supervised OR 
Supervised Injecting Center OR Supervised Injecting Facilities OR Facilities, Supervised Injecting OR 
Facility, Supervised Injecting OR Injecting Facilities, Supervised OR Injecting Facility, Supervised OR 
Supervised Injecting Facility 
Medical/Dental services 
Medical Services OR Dental Care OR Dental Health Services OR Services, Dental Health OR Health 
Services, Dental OR Dental Health Service" OR Health Service, Dental OR Service, Dental Health 
Tattooing/Piercing 
Tattooing OR Tattooings OR Tattoo* OR Body Modification, Non Therapeutic OR Body Modifications, 
Non-Therapeutic OR Non-Therapeutic Body Modifications OR Non-Therapeutic Body Modification OR 
Non Therapeutic Body Modification OR Cultural Body Modification OR Body Modification, Cultural OR 
Body Modifications, Cultural OR Cultural Body Modifications OR Body Piercing OR Body Piercings OR 
Piercings, Body OR Piercing, Body OR Ear Piercing OR Ear Piercings OR Piercing, Ear OR Piercings, 
Ear OR Nipple Piercing OR Nipple Piercings OR Piercing, Nipple OR Piercings, Nipple OR Lip Piercing 
OR Lip Piercings OR Piercing, Lip OR Piercings, Lip OR Navel Piercing OR Navel Piercings OR Piercing, 
Navel OR Piercings, Navel OR Tongue Piercing OR Piercing, Tongue OR Piercings, Tongue OR Tongue 
Piercings OR Eyebrow Piercing OR Eyebrow Piercings OR Piercing, Eyebrow OR Piercings, Eyebrow OR 
Penile Piercing 
PEP 
Post-Exposure Prophylaxis OR Post Exposure Prophylaxis OR Prophylaxis, Post-Exposure OR Post- 
Exposure Prevention OR Post Exposure Prevention OR Prevention, Post-Exposure OR Preventive Health 
Care OR Care, Preventive Health OR Health Care, Preventive OR Services, Preventive Health OR 
Preventive Health OR Health, Preventive OR Health Services, Preventive OR Health Service, Preventive 
OR Preventive Health Service OR Service, Preventive Health OR Preventive Health Programs OR Health 
Program, Preventive OR Health Programs, Preventive OR Preventive Health Program OR Program, 
Preventive Health OR Programs, Preventive Health OR Preventive Programs OR Preventive Program OR 
Program, Preventive OR Programs, Preventive 
Testing Counseling 
Counseling OR Counselors OR Counselor 
Treatment, Care, Support 
Is already covered 
TB 
Is already mentioned above 
PMTCT 
PMTCT OR Mother-to-Child Transmission 
STDs 
Sexually Transmitted Diseases OR Disease, Sexually Transmitted OR Diseases, Sexually Transmitted 
OR Sexually Transmitted Disease OR STIs OR STI OR Venereal Diseases OR Disease, Venereal OR 
Diseases, Venereal OR Venereal Disease OR Sexually Transmitted Infections OR Infection, Sexually 
Transmitted OR Infections, Sexually Transmitted OR Sexually Transmitted Infection OR Transmitted 
Infection, Sexually OR Transmitted Infections, Sexually OR STDs OR Sexually Transmitted Diseases, 
Viral OR Viral Sexually Transmitted Disease OR Venereal Diseases, Viral OR Viral Venereal Diseases 
OR Disease, Viral Venereal OR Diseases, Viral Venereal OR Venereal Disease, Viral OR Viral Venereal 
Disease OR Sexually Transmitted Disease, Viral OR Viral Sexually Transmitted Diseases 
Viral Hepatitis 
Is already mentioned above 
Occupational hazards 
Occupational Exposure OR Exposure, Occupational OR Exposures, Occupational OR Occupational 
Exposures 
 
